Immunologic Agents : Immunomodulators
IACTE1 “Actemra Infusion ” 200 mg/ 10 ml/vial
IACTE2 “Actemra Infusion” 80 mg/ 4 ml/vial
適應症：類風濕性關節炎(RA) -Actemra 合併Methotrexate(MTX)可用於治療成年人中度至重度類風濕性關節炎，曾使用一種或一種以上之DMARD藥物治療或腫瘤壞死因子拮抗劑(TNF antagonist)治療而反應不佳或無法耐受的患者。在這些患者中，若病患對MTX無法耐受或不適合繼續投與MTX，可給予Actemra單獨治療。全身性幼年型原發性關節炎(SJIA) -Actemra適用於治療2歲(含)以上的活動性全身性幼年型原發性關節炎患者，且對NSAID及類固醇治療反應不佳或無法耐受者。
Usual dose:
Adult: Rheumatoid arthritis (Moderate to Severe), in patients who had an inadequate response to disease modifying antirheumatic therapy: 4 mg/kg IV infusion over 1 hour q4w; increase to 8 mg/kg q4w based on clinical response; doses exceeding 800 mg per infusion are not recommended.
Pediatric (>=2 years, < 30 kg): 12 mg/kg IV infusion over 1 hour q2w. (>=2 years, > 30 kg): 8 mg/kg IV infusion over 1 hour q2w.
Adverse effect:
Common: hypertension, rash, diarrhea, upper abdominal pain, ALT/SGPT level raised, AST/SGOT, dizziness, headache, nasopharyngitis.
Serious: injection site reaction, gastrointestinal perforation, decreased platelet count, neutropenia, anaphylaxis, hypersensitivity reaction, upper respiratory infection, opportunistic infection, tuberculosis, cancer, infectious disease, serious infections.
健保使用規範：健保藥品給付規定第八章免疫製劑。